APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oncology Injection Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oncology Injection Drug Market Outlook and Growth Opportunities 2026

Report ID 174018960426 December 2025190 pages

Choose your research edition.

Industry ResearchOncology Injection Drug Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Injection Drug Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Oncology Injection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Injection Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Injection Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Oncology Injection Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oncology Injection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oncology Injection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oncology Injection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oncology Injection Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oncology Injection Drug market include AdvaCare, Allos Therapeutics, Alza, Celgene, CordenPharma, Debiopharm, Ferring Pharmaceuticals, Genzyme and Merrimack, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oncology Injection Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oncology Injection Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncology Injection Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oncology Injection Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Oncology Injection Drug Segment by Company

AdvaCare

Allos Therapeutics

Alza

Celgene

CordenPharma

Debiopharm

Ferring Pharmaceuticals

Genzyme

Merrimack

Millennium Pharmaceuticals

Pharmascience

Praecis Pharmaceuticals

S.G. Biopharm

Taj Oncology

Eli Lilly

Oncology Injection Drug Segment by Type

Central Nervous System

Circulatory/Musculoskeletal System

Organs

Other

Oncology Injection Drug Segment by Application

Myeloma

Lymphoma

Prostate Cancer

Other

Oncology Injection Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oncology Injection Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Oncology Injection Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oncology Injection Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Oncology Injection Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Injection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Injection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Injection Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oncology Injection Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncology Injection Drug industry.

Chapter 3: Detailed analysis of Oncology Injection Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Oncology Injection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Oncology Injection Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oncology Injection Drug Industry Trends Table 2. Oncology Injection Drug Industry Drivers Table 3. Oncology Injection Drug Industry Opportunities and Challenges Table 4. Oncology Injection Drug Industry Restraints Table 5. Global Oncology Injection Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oncology Injection Drug Revenue Share by Company (2021-2026) Table 7. Global Oncology Injection Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Oncology Injection Drug Sales Volume Share by Company (2021-2026) Table 9. Global Oncology Injection Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Oncology Injection Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Oncology Injection Drug Key Company Manufacturing Base & Headquarters Table 12. Global Oncology Injection Drug Company, Product Type & Application Table 13. Global Oncology Injection Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Oncology Injection Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Central Nervous System Table 18. Significant Companies of Circulatory/Musculoskeletal System Table 19. Significant Companies of Organs Table 20. Significant Companies of Other Table 21. Global Oncology Injection Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Oncology Injection Drug Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Oncology Injection Drug Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Oncology Injection Drug Sales Volume Share by Type (2021-2026) Table 25. Global Oncology Injection Drug Sales Volume Share by Type (2027-2032) Table 26. Global Oncology Injection Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Oncology Injection Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Oncology Injection Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Oncology Injection Drug Sales Value Share by Type (2021-2026) Table 30. Global Oncology Injection Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Myeloma Table 32. Significant Companies of Lymphoma Table 33. Significant Companies of Prostate Cancer Table 34. Significant Companies of Other Table 35. Global Oncology Injection Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Oncology Injection Drug Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Oncology Injection Drug Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Oncology Injection Drug Sales Volume Share by Application (2021-2026) Table 39. Global Oncology Injection Drug Sales Volume Share by Application (2027-2032) Table 40. Global Oncology Injection Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Oncology Injection Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Oncology Injection Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Oncology Injection Drug Sales Value Share by Application (2021-2026) Table 44. Global Oncology Injection Drug Sales Value Share by Application (2027-2032) Table 45. Global Oncology Injection Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Oncology Injection Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Oncology Injection Drug Sales Market Share by Region (2021-2026) Table 48. Global Oncology Injection Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Oncology Injection Drug Sales Market Share by Region (2027-2032) Table 50. Global Oncology Injection Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Oncology Injection Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Oncology Injection Drug Sales Value Share by Region (2021-2026) Table 53. Global Oncology Injection Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Oncology Injection Drug Sales Value Share by Region (2027-2032) Table 55. Global Oncology Injection Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Oncology Injection Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Oncology Injection Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Oncology Injection Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Oncology Injection Drug Sales by Country (2021-2026) & (K Units) Table 60. Global Oncology Injection Drug Sales Market Share by Country (2021-2026) Table 61. Global Oncology Injection Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Oncology Injection Drug Sales Market Share by Country (2027-2032) Table 63. Global Oncology Injection Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Oncology Injection Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Oncology Injection Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Oncology Injection Drug Sales Value Market Share by Country (2027-2032) Table 67. AdvaCare Company Information Table 68. AdvaCare Business Overview Table 69. AdvaCare Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. AdvaCare Oncology Injection Drug Product Portfolio Table 71. AdvaCare Recent Development Table 72. Allos Therapeutics Company Information Table 73. Allos Therapeutics Business Overview Table 74. Allos Therapeutics Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Allos Therapeutics Oncology Injection Drug Product Portfolio Table 76. Allos Therapeutics Recent Development Table 77. Alza Company Information Table 78. Alza Business Overview Table 79. Alza Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Alza Oncology Injection Drug Product Portfolio Table 81. Alza Recent Development Table 82. Celgene Company Information Table 83. Celgene Business Overview Table 84. Celgene Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Celgene Oncology Injection Drug Product Portfolio Table 86. Celgene Recent Development Table 87. CordenPharma Company Information Table 88. CordenPharma Business Overview Table 89. CordenPharma Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. CordenPharma Oncology Injection Drug Product Portfolio Table 91. CordenPharma Recent Development Table 92. Debiopharm Company Information Table 93. Debiopharm Business Overview Table 94. Debiopharm Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Debiopharm Oncology Injection Drug Product Portfolio Table 96. Debiopharm Recent Development Table 97. Ferring Pharmaceuticals Company Information Table 98. Ferring Pharmaceuticals Business Overview Table 99. Ferring Pharmaceuticals Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Ferring Pharmaceuticals Oncology Injection Drug Product Portfolio Table 101. Ferring Pharmaceuticals Recent Development Table 102. Genzyme Company Information Table 103. Genzyme Business Overview Table 104. Genzyme Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Genzyme Oncology Injection Drug Product Portfolio Table 106. Genzyme Recent Development Table 107. Merrimack Company Information Table 108. Merrimack Business Overview Table 109. Merrimack Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Merrimack Oncology Injection Drug Product Portfolio Table 111. Merrimack Recent Development Table 112. Millennium Pharmaceuticals Company Information Table 113. Millennium Pharmaceuticals Business Overview Table 114. Millennium Pharmaceuticals Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Millennium Pharmaceuticals Oncology Injection Drug Product Portfolio Table 116. Millennium Pharmaceuticals Recent Development Table 117. Pharmascience Company Information Table 118. Pharmascience Business Overview Table 119. Pharmascience Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Pharmascience Oncology Injection Drug Product Portfolio Table 121. Pharmascience Recent Development Table 122. Praecis Pharmaceuticals Company Information Table 123. Praecis Pharmaceuticals Business Overview Table 124. Praecis Pharmaceuticals Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Praecis Pharmaceuticals Oncology Injection Drug Product Portfolio Table 126. Praecis Pharmaceuticals Recent Development Table 127. S.G. Biopharm Company Information Table 128. S.G. Biopharm Business Overview Table 129. S.G. Biopharm Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. S.G. Biopharm Oncology Injection Drug Product Portfolio Table 131. S.G. Biopharm Recent Development Table 132. Taj Oncology Company Information Table 133. Taj Oncology Business Overview Table 134. Taj Oncology Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Taj Oncology Oncology Injection Drug Product Portfolio Table 136. Taj Oncology Recent Development Table 137. Eli Lilly Company Information Table 138. Eli Lilly Business Overview Table 139. Eli Lilly Oncology Injection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Eli Lilly Oncology Injection Drug Product Portfolio Table 141. Eli Lilly Recent Development Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Oncology Injection Drug Distributors List Table 145. Oncology Injection Drug Customers List Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Oncology Injection Drug Product Image Figure 2. Global Oncology Injection Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology Injection Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Oncology Injection Drug Sales (2021-2032) & (K Units) Figure 5. Global Oncology Injection Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Oncology Injection Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Central Nervous System Image Figure 10. Circulatory/Musculoskeletal System Image Figure 11. Organs Image Figure 12. Other Image Figure 13. Global Oncology Injection Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Oncology Injection Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Oncology Injection Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Oncology Injection Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Oncology Injection Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Oncology Injection Drug Sales Value Share by Type (2021-2032) Figure 19. Myeloma Image Figure 20. Lymphoma Image Figure 21. Prostate Cancer Image Figure 22. Other Image Figure 23. Global Oncology Injection Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Oncology Injection Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Oncology Injection Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Oncology Injection Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Oncology Injection Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Oncology Injection Drug Sales Value Share by Application (2021-2032) Figure 29. Global Oncology Injection Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Oncology Injection Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Oncology Injection Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Oncology Injection Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Oncology Injection Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Oncology Injection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Oncology Injection Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Oncology Injection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Oncology Injection Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Oncology Injection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Oncology Injection Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Oncology Injection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Oncology Injection Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Oncology Injection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Oncology Injection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Oncology Injection Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Oncology Injection Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Central Nervous System
  • Circulatory/Musculoskeletal System
  • Organs
  • Other
Applications
  • Myeloma
  • Lymphoma
  • Prostate Cancer
  • Other
Companies covered
  • AdvaCare
  • Allos Therapeutics
  • Alza
  • Celgene
  • CordenPharma
  • Debiopharm
  • Ferring Pharmaceuticals
  • Genzyme
  • Merrimack
  • Millennium Pharmaceuticals
  • Pharmascience
  • Praecis Pharmaceuticals
  • S.G. Biopharm
  • Taj Oncology
  • Eli Lilly

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oncology Injection Drug Sales Value (2021-2032)
  4. 1.2.2 Global Oncology Injection Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Oncology Injection Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Oncology Injection Drug Market Dynamics
  1. 2.1 Oncology Injection Drug Industry Trends
  2. 2.2 Oncology Injection Drug Industry Drivers
  3. 2.3 Oncology Injection Drug Industry Opportunities and Challenges
  4. 2.4 Oncology Injection Drug Industry Restraints
3 Oncology Injection Drug Market by Company
  1. 3.1 Global Oncology Injection Drug Company Revenue Ranking in 2025
  2. 3.2 Global Oncology Injection Drug Revenue by Company (2021-2026)
  3. 3.3 Global Oncology Injection Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Oncology Injection Drug Average Price by Company (2021-2026)
  5. 3.5 Global Oncology Injection Drug Company Ranking (2024-2026)
  6. 3.6 Global Oncology Injection Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Oncology Injection Drug Company Product Type and Application
  8. 3.8 Global Oncology Injection Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Oncology Injection Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Oncology Injection Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Oncology Injection Drug Market by Type
  1. 4.1 Oncology Injection Drug Type Introduction
  2. 4.1.1 Central Nervous System
  3. 4.1.2 Circulatory/Musculoskeletal System
  4. 4.1.3 Organs
  5. 4.1.4 Other
  6. 4.2 Global Oncology Injection Drug Sales Volume by Type
  7. 4.2.1 Global Oncology Injection Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Oncology Injection Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Oncology Injection Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Oncology Injection Drug Sales Value by Type
  11. 4.3.1 Global Oncology Injection Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Oncology Injection Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Oncology Injection Drug Sales Value Share by Type (2021-2032)
5 Oncology Injection Drug Market by Application
  1. 5.1 Oncology Injection Drug Application Introduction
  2. 5.1.1 Myeloma
  3. 5.1.2 Lymphoma
  4. 5.1.3 Prostate Cancer
  5. 5.1.4 Other
  6. 5.2 Global Oncology Injection Drug Sales Volume by Application
  7. 5.2.1 Global Oncology Injection Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Oncology Injection Drug Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Oncology Injection Drug Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Oncology Injection Drug Sales Value by Application
  11. 5.3.1 Global Oncology Injection Drug Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Oncology Injection Drug Sales Value by Application (2021-2032)
  13. 5.3.3 Global Oncology Injection Drug Sales Value Share by Application (2021-2032)
6 Oncology Injection Drug Regional Sales and Value Analysis
  1. 6.1 Global Oncology Injection Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oncology Injection Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Oncology Injection Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Oncology Injection Drug Sales by Region (2027-2032)
  5. 6.3 Global Oncology Injection Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Oncology Injection Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Oncology Injection Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Oncology Injection Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Oncology Injection Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Oncology Injection Drug Sales Value (2021-2032)
  12. 6.6.2 North America Oncology Injection Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Oncology Injection Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Oncology Injection Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Oncology Injection Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Oncology Injection Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Oncology Injection Drug Sales Value (2021-2032)
  21. 6.9.2 South America Oncology Injection Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Oncology Injection Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Oncology Injection Drug Sales Value Share by Country, 2025 VS 2032
7 Oncology Injection Drug Country-level Sales and Value Analysis
  1. 7.1 Global Oncology Injection Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oncology Injection Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Oncology Injection Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Oncology Injection Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Oncology Injection Drug Sales by Country (2027-2032)
  6. 7.4 Global Oncology Injection Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Oncology Injection Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Oncology Injection Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Oncology Injection Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Oncology Injection Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Oncology Injection Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AdvaCare
  2. 8.1.1 AdvaCare Company Information
  3. 8.1.2 AdvaCare Business Overview
  4. 8.1.3 AdvaCare Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AdvaCare Oncology Injection Drug Product Portfolio
  6. 8.1.5 AdvaCare Recent Developments
  7. 8.2 Allos Therapeutics
  8. 8.2.1 Allos Therapeutics Company Information
  9. 8.2.2 Allos Therapeutics Business Overview
  10. 8.2.3 Allos Therapeutics Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Allos Therapeutics Oncology Injection Drug Product Portfolio
  12. 8.2.5 Allos Therapeutics Recent Developments
  13. 8.3 Alza
  14. 8.3.1 Alza Company Information
  15. 8.3.2 Alza Business Overview
  16. 8.3.3 Alza Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Alza Oncology Injection Drug Product Portfolio
  18. 8.3.5 Alza Recent Developments
  19. 8.4 Celgene
  20. 8.4.1 Celgene Company Information
  21. 8.4.2 Celgene Business Overview
  22. 8.4.3 Celgene Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Celgene Oncology Injection Drug Product Portfolio
  24. 8.4.5 Celgene Recent Developments
  25. 8.5 CordenPharma
  26. 8.5.1 CordenPharma Company Information
  27. 8.5.2 CordenPharma Business Overview
  28. 8.5.3 CordenPharma Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 CordenPharma Oncology Injection Drug Product Portfolio
  30. 8.5.5 CordenPharma Recent Developments
  31. 8.6 Debiopharm
  32. 8.6.1 Debiopharm Company Information
  33. 8.6.2 Debiopharm Business Overview
  34. 8.6.3 Debiopharm Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Debiopharm Oncology Injection Drug Product Portfolio
  36. 8.6.5 Debiopharm Recent Developments
  37. 8.7 Ferring Pharmaceuticals
  38. 8.7.1 Ferring Pharmaceuticals Company Information
  39. 8.7.2 Ferring Pharmaceuticals Business Overview
  40. 8.7.3 Ferring Pharmaceuticals Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Ferring Pharmaceuticals Oncology Injection Drug Product Portfolio
  42. 8.7.5 Ferring Pharmaceuticals Recent Developments
  43. 8.8 Genzyme
  44. 8.8.1 Genzyme Company Information
  45. 8.8.2 Genzyme Business Overview
  46. 8.8.3 Genzyme Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Genzyme Oncology Injection Drug Product Portfolio
  48. 8.8.5 Genzyme Recent Developments
  49. 8.9 Merrimack
  50. 8.9.1 Merrimack Company Information
  51. 8.9.2 Merrimack Business Overview
  52. 8.9.3 Merrimack Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Merrimack Oncology Injection Drug Product Portfolio
  54. 8.9.5 Merrimack Recent Developments
  55. 8.10 Millennium Pharmaceuticals
  56. 8.10.1 Millennium Pharmaceuticals Company Information
  57. 8.10.2 Millennium Pharmaceuticals Business Overview
  58. 8.10.3 Millennium Pharmaceuticals Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Millennium Pharmaceuticals Oncology Injection Drug Product Portfolio
  60. 8.10.5 Millennium Pharmaceuticals Recent Developments
  61. 8.11 Pharmascience
  62. 8.11.1 Pharmascience Company Information
  63. 8.11.2 Pharmascience Business Overview
  64. 8.11.3 Pharmascience Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Pharmascience Oncology Injection Drug Product Portfolio
  66. 8.11.5 Pharmascience Recent Developments
  67. 8.12 Praecis Pharmaceuticals
  68. 8.12.1 Praecis Pharmaceuticals Company Information
  69. 8.12.2 Praecis Pharmaceuticals Business Overview
  70. 8.12.3 Praecis Pharmaceuticals Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Praecis Pharmaceuticals Oncology Injection Drug Product Portfolio
  72. 8.12.5 Praecis Pharmaceuticals Recent Developments
  73. 8.13 S.G. Biopharm
  74. 8.13.1 S.G. Biopharm Company Information
  75. 8.13.2 S.G. Biopharm Business Overview
  76. 8.13.3 S.G. Biopharm Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 S.G. Biopharm Oncology Injection Drug Product Portfolio
  78. 8.13.5 S.G. Biopharm Recent Developments
  79. 8.14 Taj Oncology
  80. 8.14.1 Taj Oncology Company Information
  81. 8.14.2 Taj Oncology Business Overview
  82. 8.14.3 Taj Oncology Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Taj Oncology Oncology Injection Drug Product Portfolio
  84. 8.14.5 Taj Oncology Recent Developments
  85. 8.15 Eli Lilly
  86. 8.15.1 Eli Lilly Company Information
  87. 8.15.2 Eli Lilly Business Overview
  88. 8.15.3 Eli Lilly Oncology Injection Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Eli Lilly Oncology Injection Drug Product Portfolio
  90. 8.15.5 Eli Lilly Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oncology Injection Drug Value Chain Analysis
  2. 9.1.1 Oncology Injection Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oncology Injection Drug Sales Mode & Process
  6. 9.2 Oncology Injection Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oncology Injection Drug Distributors
  9. 9.2.3 Oncology Injection Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst